Bottles filled on an automated production line. Photo: Mina Rad / Unsplash
Pharma, Biotechnology & Life Sciences

Pharmaceuticals

From plant to prescriber, the integrity programme a regulator expects to see.

What we see

The issues clients bring us.

  • Data integrity at plants and labs
  • UCPMP 2024 compliance
  • HCP-payment reporting in US operations (Sunshine Act)
  • Counterfeit medicines
  • Distributor diversion and scheme leakage
  • Export-market bribery risk
How BDI helps

What we do about them.

  • UCPMP Compliance and HCP Spend Assurance
  • Sunshine Act and Open Payments assurance for US operations
  • Data-integrity investigations
  • Distributor and trade-scheme audits
  • Anti-counterfeiting programmes
  • Global head-of-investigations support
Platforms for Pharmaceuticals

Keep the record with BDI's governance tools.

Pharma, Biotechnology & Life Sciences: market context

The numbers behind the risk.

India

The pharmacy of the world, now held to tighter manufacturing, marketing and data standards at home and abroad.

US$60 bn
domestic pharma market in FY26, projected to reach US$130 bn by 2030
Source: IBEF
US$31 bn
pharmaceutical exports in FY26
Source: IBEF
3rd
largest producer by volume; about 20% of global generics supply
Source: IBEF
33%
of surveyed consumers encountered a counterfeit healthcare product in the past year
Source: The Week, on the ASPA–CRISIL State of Counterfeiting in India 2025 report

Regulatory and market updates

  • Revised Schedule M enforcement

    MSME units that applied for extension had until 31 December 2025; the DCGI has ordered state regulators to inspect units for compliance.Source: The Week (PTI)

  • UCPMP 2024

    The Uniform Code for Pharmaceutical Marketing Practices 2024 bans gifts to healthcare professionals, caps samples, bars CME events abroad and requires event spend to be published, with a self-declaration by the executive head within two months of each financial year.Source: Nishith Desai Associates

  • UCMPMD 2024 for medical devices

    A parallel Uniform Code for Marketing Practices in Medical Devices was notified in September 2024, extending similar rules on gifts, samples, hospitality and self-declarations to device companies.Source: Outlook Business

  • Biopharma SHAKTI

    ₹10,000 crore over five years announced in the Union Budget 2026-27 to build biopharma capability.Source: IBEF

Also in Pharma, Biotechnology & Life Sciences
Start a confidential conversation

Seeing this in your business? Start with a confidential call.